title: [An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia].
abstract: OBJECTIVE
  To investigate the effect of IL-2, IFN and bcr-abl AS-ODN on bone marrow purging in vitro for patients with chronic myelogenous leukemia (CML).
  
  
  METHODS
  By amplifying in vitro clone forming culture, and purging the bone marrow of 5 CML patients through different combined use of IL-2, IFN and bcr-abl AS-ODN, we compared the effects of 4 combined regimens.
  
  
  RESULTS
  It was found that the suppressive effects of the 4th regimen combining IL-2 (800 U/ml), IFN (800 u/ml) and bcr-abl AS-ODN (30 micrograms/ml) on leukemia cell clone forming unit (CFU) were significantly different from the suppressive effects of the other 3 regimens (P < 0.01). With the use of the 4th regimen, the GM-CFU and L-CFU survival rates were 26.91% and 3.49% respectively (P < 0.01).
  
  
  CONCLUSIONS
  The combined regimen of IL-2 (800 U/ml), IFN (800 u/ml) and bcr-abl AS-ODN (30 micrograms/ml) has good effect on selective CML bone marrow purging in vitro and can be used in clinical purging of CML bone marrow.
authors.affiliation: Department of Hematology, Shenzhen Hospital, Beijing University, Shenzhen 518036, China.
authors.forename: J
authors.initials: J
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Jiang
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.forename: D
authors.initials: D
authors.lastname: Wu
authors.forename: G
authors.initials: G
authors.lastname: Yang
authors.forename: X
authors.initials: X
authors.lastname: Huang
authors.forename: X
authors.initials: X
authors.lastname: Wei
mesh_terms: D001854:Bone Marrow Cells / Q000166:cytology; D016465:Bone Marrow Purging; D016026:Bone Marrow Transplantation; D002469:Cell Separation; D002478:Cells, Cultured; D016044:Fusion Proteins, bcr-abl / Q000494:pharmacology; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D007963:Leukocytes, Mononuclear / Q000166:cytology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology
chemical_list: D016898:Interferon-alpha; D007376:Interleukin-2; D016376:Oligonucleotides, Antisense; D016044:Fusion Proteins, bcr-abl